ALV-200: The AMYR3-Selective Amylin Agonist Betting That You Can Split Amylin's Benefits From Its Nausea (July 28, 2026)
Table of Contents
Amylin is the second pillar - but it comes with a tax
After GLP-1, amylin is the most clinically validated hormone pathway in obesity medicine. Amylin is co-secreted with insulin from the pancreas, and it curbs appetite, slows gastric emptying and reduces food intake. That is why cagrilintide (paired with semaglutide as CagriSema), petrelintide, eloralintide and a wave of other amylin analogs have drawn tens of billions of dollars in deals during the 2026 'amylin renaissance.' But amylin agonism carries its own tax: nausea, vomiting and food aversion that limit how hard you can push the dose. The question Alveus Therapeutics is asking with ALV-200 is whether that tax is actually separable from the benefit - and its answer sits in the biology of which receptor does what.
One hormone, several receptors
Amylin does not signal through a single receptor. It acts on the calcitonin receptor (CTR) and on three amylin receptors - AMYR1, AMYR2 and AMYR3 - each of which is the calcitonin receptor complexed with a receptor-activity-modifying protein (RAMP1, RAMP2 or RAMP3). Most amylin analogs in the clinic today are dual amylin-calcitonin receptor agonists, or DACRAs: they deliberately activate CTR along with the amylin receptors. That broad activation delivers weight loss, but Alveus's thesis is that it also delivers the side effects. In the company's framing, the beneficial metabolic effects of amylin - including the prized preservation of lean mass during weight loss - are driven mainly through AMYR3, while the gastrointestinal adverse effects such as nausea and aversion are driven mainly through CTR.
ALV-200's bet: hit AMYR3, spare CTR
ALV-200 is engineered as a highly selective AMYR3 peptide agonist with significant selectivity over the calcitonin receptor. If the receptor-division-of-labor hypothesis holds, that selectivity is exactly what you want: keep the AMYR3-driven appetite suppression, weight loss and lean-mass preservation, while sidestepping the CTR-driven nausea. In Alveus's preclinical models, ALV-200 maintained weight-loss efficacy while showing meaningful CTR selectivity, and it is designed for once-weekly subcutaneous dosing. It is worth being clear about the stage: this is a preclinical, IND-enabling asset. The selectivity story is mechanistically elegant, but whether it translates into a genuinely better-tolerated drug in humans is still an open, testable question.
Why lean mass keeps coming up
One reason ALV-200's design is interesting is the lean-mass angle. A recurring critique of GLP-1-based weight loss is that a meaningful fraction of the weight lost is lean mass, not just fat. Much of the next generation of obesity drugs - from GIPR-antagonist designs like Alveus's own ALV-100 and Amgen's MariTide to amylin analogs - is being pitched partly on improving the 'quality' of weight loss by preserving muscle. Alveus attributes amylin's lean-mass-preserving effect specifically to AMYR3, which is part of why an AMYR3-selective agonist is an attractive shot: in principle it concentrates the mechanism most associated with the benefit researchers care about most.
The company behind it
ALV-200 comes from Alveus Therapeutics, a clinical-stage obesity and metabolic-disease company that launched from stealth on January 8, 2026 with a $159.8 million Series A led by New Rhein Healthcare Investors, Andera Partners and Omega Funds, with participation from Sanofi Capital, Kurma Partners and others; the round was upsized to roughly $197 million in a second and final close in February 2026. The company is headquartered in Philadelphia with R&D operations in Copenhagen, and its leadership is drawn from metabolic-disease programs at Novo Nordisk and Eli Lilly. Alveus's lead clinical asset is ALV-100, a bifunctional GIPR-antagonist / GLP-1R-agonist fusion protein already in a Phase 1b obesity trial; ALV-200 is the injectable centerpiece of a broader amylin franchise that also includes oral small molecules and multifunctional formats. Alveus has said it expects to start first-in-human studies of ALV-200 within roughly 18 months of launch.
How it fits the amylin field - and the honest caveats
ALV-200 sits alongside the DACRAs (cagrilintide, petrelintide) and the growing set of amylin and dual GLP-1/amylin agents (amycretin, eloralintide) as a distinct, receptor-selective approach rather than a me-too analog. If it works as hoped, it could define a cleaner-tolerability lane within amylin biology. But the caveats are real and worth stating plainly: there is no human data yet; the AMYR3-benefit / CTR-side-effect split is a hypothesis, not an established fact in people; and receptor-selectivity that looks clean in preclinical assays does not always survive contact with human physiology. ALV-200 is a well-financed, mechanistically thoughtful bet on the next phase of amylin drugs - one to watch as it moves toward the clinic, not a proven therapy. It is an investigational candidate, not a supplement or research chemical, and any 'ALV-200' offered for sale is unverified.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Alveus Therapeutics - Science (ALV-200 AMYR3-selective amylin agonist) Source
- [2] Alveus Therapeutics Launches with $160 Million Series A Financing (Jan 8, 2026) - GlobeNewswire Source
- [3] Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A (~$197M) - BioSpace Source
- [4] Equipped with $160M Series A, Alveus debuts into crowded obesity development landscape - Fierce Biotech Source
- [5] The Amylin Renaissance: Forty Programs, $19 Billion in Deals - PatentVest Source
Related Articles
Alveus Therapeutics' ALV-100, a bifunctional GIPR-antagonist / GLP-1-agonist peptide, has entered a Phase 1b obesity trial backed by a ~$197M Series A, joining the MariTide-style combination class focused on the quality and durability of weight loss; meanwhile amycretin's Phase 2 detail (11.9% placebo-adjusted weekly subcutaneous weight loss) heads toward Phase 3 and the ADA 2026 Scientific Sessions (June 5-8, New Orleans) prepares to release late-breaking obesity data on June 5.
Petrelintide and the Amylin Moment: Zealand and Roche's Phase 2 Win on Tolerability Heads to ADA 2026 — June 1, 2026 Peptide Research Update
Zealand Pharma and Roche's amylin analog petrelintide delivered up to 10.7% mean weight loss in the Phase 2 ZUPREME-1 trial with GI side effects comparable to placebo - a tolerability-first profile heading to ADA 2026 as the amylin class matures into the next pillar of obesity care.
The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026
Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.'
ASC39: An Oral Amylin Pill Aiming to Match Injectable Amylin Drugs (July 30, 2026)
The best amylin obesity drugs are injections. ASC39, from Ascletis, is a once-daily pill that matched Eli Lilly's injectable eloralintide on amylin potency, selectivity and weight loss in preclinical tests - and it is being paired with an oral GLP-1 agonist into a single tablet. Here is what is known, and what is not.
MET-233i: The Once-Monthly Amylin Injection Built to Pair With a Monthly GLP-1 (July 31, 2026)
Most amylin obesity drugs are weekly shots. MET-233i, from Metsera and now Pfizer, is an amylin analog with a ~19-day half-life - the longest reported for the class - that produced up to 8.4% weight loss in Phase 1 and is engineered to be combined with a monthly GLP-1 agonist into one once-monthly injection. Here is what is known, and what is not.